[Oxaliplatin and ovarian cancer].

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Bulletin du Cancer

• Publication date

  2006-02-01

• Fields of study

  Medicine

• Identifiers
  PMID 16483943
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer.

  2006cited by this paper
• Gemcitabine Combined with Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Patients with Advanced Ovarian Cancer Refractory or Resistant to Platinum and Taxane

  2005cited by this paper
• Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.

  2004cited by this paper
• Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy.

  2004cited by this paper
• cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance

  2004cited by this paper
• Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study.

  2004cited by this paper
• Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study.

  2003cited by this paper
• Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.

  2002cited by this paper
• Ovarian cancer: progress and continuing controversies in management.

  2002cited by this paper
• Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients.

  2002cited by this paper
• Oxaliplatin: A Review of Evolving Concepts

  2002cited by this paper
• Current and future potential roles of the platinum drugs in the treatment of ovarian cancer.

  2001cited by this paper
• Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients.

  2001cited by this paper
• Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

  2000cited by this paper
• Oxaliplatin: a review of preclinical and clinical studies.

  1998cited by this paper
• Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.

  1997cited by this paper
• Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.

  1996cited by this paper
• Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer.

  1996cited by this paper
• Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.

  1991cited by this paper
• Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.

  1991cited by this paper

• Common Chemical Inductors of Replication Stress: Focus on Cell-Based Studies

  2017cites this paper
• EFFECT OF CHRONOMODULATED ARTESUNATE ON RENAL AND HAEMATOLOGICAL TOXICITY IN CISPLATIN-TREATED WISTAR RATS

  2017cites this paper
• Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects

  2011cites this paper
• Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice

  2011cites this paper
• A Dose-Escalation Study of Pegylated Liposomal Doxorubicin and Oxaliplatin in Patients with Advanced Solid Tumors

  2007cites this paper